Non-sexual implications of phosphodiesterase type 5 inhibitors

T Mostafa - Sexual Medicine Reviews, 2017 - academic.oup.com
Abstract Introduction Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate
monophosphate specifically to 5′ guanylate monophosphate, promoting corporeal …

Useful implications of low-dose long-term use of PDE-5 inhibitors

T Mostafa - Sexual Medicine Reviews, 2016 - academic.oup.com
Abstract Introduction Phosphodiesterase type 5 (PDE-5) hydrolyzes cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP, promoting successful corporeal vascular …

Cardiovascular effects of phosphodiesterase type 5 inhibitors

C Vlachopoulos, N Ioakeimidis… - The Journal of …, 2009 - academic.oup.com
ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-
line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an …

Cardiovascular safety of phosphodiesterase type 5 inhibitors after nearly 2 decades on the market

RA Kloner, I Goldstein, MG Kirby… - Sexual Medicine …, 2018 - academic.oup.com
Abstract Background The phosphodiesterase-5 (PDE5) inhibitors that have been available
for nearly 20 years are highly effective in treating erectile dysfunction and have been …

[HTML][HTML] The effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews

N Pyrgidis, I Mykoniatis, AB Haidich, M Tirta… - Frontiers in …, 2021 - frontiersin.org
Background: Multiple systematic reviews explore the effect of phosphodiesterase type 5
(PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific …

Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses

T Mostafa - The journal of sexual medicine, 2008 - academic.oup.com
ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP. PDE5 inhibitors were a breakthrough …

Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction

L Gao, L Yang, S Qian, T Li, P Han, J Yuan - International Journal of …, 2016 - Elsevier
Background Clinical studies evaluating the effectiveness and safety of phosphodiesterase
type 5 inhibitors (PDE5is) for female sexual dysfunction have reported conflicting results …

Recreational use of oral PDE5 inhibitors: the other side of midnight

T Mostafa, MF Alghobary - Sexual Medicine Reviews, 2022 - academic.oup.com
ABSTRACT Background Nowadays, Oral phosphodiesterase type 5 inhibitors (PDE5Is) are
widely used for the treatment of erectile dysfunction (ED). However, these drugs have …

Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview

T Mostafa, M Alghobary, NS Hanafy… - Sexual Medicine …, 2023 - academic.oup.com
Background Phosphodiesterase type 5 inhibitors (PDE5Is), due to their efficacy and
tolerable profile for more than 2 decades, are considered a good addition to the available …

PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes

RC Rosen, KE McKenna - Annual review of sex research, 2002 - Taylor & Francis
Abstract Phosphodiesterase type-5 (PDE-5) inhibitors are a new class of vasoactive drugs
that have been developed for treatment of erectile dysfunction (ED). The mechanism of …